JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

13.51 2.5

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.92

Máximo

13.51

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.989 49.8
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+50.38% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.3B
Abertura anterior	11.01
Fecho anterior	13.51

Sentimento de Notícias

By Acuity

50%

180 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mai. de 2026, 23:43 UTC

Notícias Principais

New Zealand's Unemployment Rate Falls in 1Q

5 de mai. de 2026, 23:20 UTC

Ações em Alta

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 de mai. de 2026, 21:48 UTC

Ganhos

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 de mai. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 de mai. de 2026, 00:00 UTC

Conversa de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 de mai. de 2026, 22:26 UTC

Conversa de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 de mai. de 2026, 22:20 UTC

Conversa de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 de mai. de 2026, 22:08 UTC

Ganhos

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 de mai. de 2026, 22:07 UTC

Ganhos

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Rev $1.2B >PAAS

5 de mai. de 2026, 21:42 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:38 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:30 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:29 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:26 UTC

Ganhos

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q EPS 39c >ALC.EB

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 de mai. de 2026, 21:24 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:18 UTC

Ganhos

Mistras Backs 2026 Rev $730M-$750M >MG

5 de mai. de 2026, 21:17 UTC

Ganhos

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 de mai. de 2026, 21:15 UTC

Ganhos

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 de mai. de 2026, 21:12 UTC

Ganhos

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 de mai. de 2026, 21:11 UTC

Ganhos

SSR Mining 1Q Rev $581.8M >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q EPS $1.16 >SSRM

5 de mai. de 2026, 21:08 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:01 UTC

Ganhos

Intact Financial 1Q EPS C$4.12 >IFC.T

5 de mai. de 2026, 21:01 UTC

Ações em Alta

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

50.38% parte superior

Previsão para 12 meses

Média 20 USD 50.38%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

180 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.